ALQGC Stock Overview
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
Quantum Genomics Société Anonyme Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €0.10 |
52 Week High | €0.21 |
52 Week Low | €0.08 |
Beta | 0.71 |
1 Month Change | 2.78% |
3 Month Change | -2.08% |
1 Year Change | -20.46% |
3 Year Change | -97.74% |
5 Year Change | -98.06% |
Change since IPO | -99.48% |
Recent News & Updates
Recent updates
Shareholder Returns
ALQGC | FR Biotechs | FR Market | |
---|---|---|---|
7D | -0.2% | 1.7% | -0.3% |
1Y | -20.5% | -2.2% | 10.1% |
Return vs Industry: ALQGC underperformed the French Biotechs industry which returned -2.1% over the past year.
Return vs Market: ALQGC underperformed the French Market which returned 10.2% over the past year.
Price Volatility
ALQGC volatility | |
---|---|
ALQGC Average Weekly Movement | 9.9% |
Biotechs Industry Average Movement | 6.4% |
Market Average Movement | 4.3% |
10% most volatile stocks in FR Market | 9.9% |
10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALQGC has not had significant price volatility in the past 3 months.
Volatility Over Time: ALQGC's weekly volatility has decreased from 19% to 10% over the past year, but is still higher than 75% of French stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2005 | 4 | Jean-Philippe Milon | https://www.quantum-genomics.com |
Quantum Genomics Société Anonyme, a biopharmaceutical company, engages in the development of drugs to treat cardiovascular diseases. The company develops its drugs based on brain inhibition mechanism of Aminopeptidase A: BAPAI, a triple-action therapeutic platform primarily to treat high blood pressure and heart failure. It is developing firibastat, a treatment for high blood pressure, and in combination with others anti-hypertensive drugs.
Quantum Genomics Société Anonyme Fundamentals Summary
ALQGC fundamental statistics | |
---|---|
Market cap | €3.60m |
Earnings (TTM) | -€3.17m |
Revenue (TTM) | €19.80k |
182.1x
P/S Ratio-1.1x
P/E RatioIs ALQGC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ALQGC income statement (TTM) | |
---|---|
Revenue | €19.80k |
Cost of Revenue | €1.44m |
Gross Profit | -€1.42m |
Other Expenses | €1.75m |
Earnings | -€3.17m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.091 |
Gross Margin | -7,169.57% |
Net Profit Margin | -16,018.12% |
Debt/Equity Ratio | 622.2% |
How did ALQGC perform over the long term?
See historical performance and comparison